Get the Stockscreener App
2.53
7.20%
0.17
Pre-market:
2.50
-0.03
-1.19%
Sana Biotechnology Inc stock is traded at $2.53, with a volume of 1.87M.
It is up +7.20% in the last 24 hours and down -40.19% over the past month.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others.
See More
Previous Close:
$2.36
Open:
$2.42
24h Volume:
1.87M
Relative Volume:
1.33
Market Cap:
$564.87M
Revenue:
-
Net Income/Loss:
$-283.26M
P/E Ratio:
-1.3386
EPS:
-1.89
Net Cash Flow:
$-273.61M
1W Performance:
-4.89%
1M Performance:
-40.19%
6M Performance:
-70.68%
1Y Performance:
-41.16%
1-Day Range:
$2.33
$2.54
1-Week Range:
$2.29
$2.755
52-Week Range:
$2.29
$12.00
Sana Biotechnology Inc Stock (SANA) Company Profile
Name
Sana Biotechnology Inc
Sector
Industry
Phone
(206) 701-7914
Address
188 EAST BLAINE STREET, SUITE 400, SEATTLE
Compare SANA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| SANA | 2.53 | 564.87M | 0 | -283.26M | -273.61M | -1.89 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Sana Biotechnology Inc Stock (SANA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-25-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Aug-14-23 | Initiated | TD Cowen | Market Perform |
| May-02-23 | Initiated | H.C. Wainwright | Neutral |
| Mar-01-21 | Initiated | BofA Securities | Buy |
| Mar-01-21 | Initiated | Goldman | Neutral |
| Mar-01-21 | Initiated | JP Morgan | Neutral |
| Mar-01-21 | Initiated | Morgan Stanley | Overweight |
View All
Sana Biotechnology Inc Stock (SANA) Latest News
Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies - Quantisnow
Sana Biotechnology: The Story Becomes Murkier (NASDAQ:SANA) - Seeking Alpha
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc.SANA - PR Newswire
Sana Biotechnology (NASDAQ:SANA) Reaches New 1-Year LowHere's Why - MarketBeat
Layoff Tracker: Adaptimmune Downsizes by 33% in Strategic Realignment - BioSpace
10 Stocks Jeff Bezos Is Buying | Investing - U.S News & World Report Money
Sana Biotechnology's SWOT analysis: stock outlook amid strategic pivot - Investing.com India
Flagship Pioneering Appoints Craig Williams as CEO-Partner and Chief Executive Officer of Apriori Bio - Quantisnow
Sana Biotechnology, Inc. (NASDAQ:SANA) Holdings Lowered by Baillie Gifford & Co. - MarketBeat
Sana Biotechnology stock hits 52-week low at $2.75 By Investing.com - Investing.com Australia
FMR LLC's Strategic Acquisition of Sana Biotechnology Inc Shares - GuruFocus.com
Sana Biotechnology stock hits 52-week low at $2.75 - Investing.com India
Sana Biotech sustains stock target with Buy rating on Q3 earnings - Investing.com Nigeria
Analyst keeps Buy on Sana Biotechnology, adjusts outlook as blood cancer competition rises - Investing.com Canada
Sana Biotechnology's SWOT analysis: stock outlook amid strategic pivot By Investing.com - Investing.com Canada
Sana Biotechnology (NASDAQ:SANA) Hits New 1-Year LowWhat's Next? - MarketBeat
Sana Biotechnology Inc Still Hasn’t Convinced Analysts? - Stocks Register
HC Wainwright Reaffirms "Buy" Rating for Sana Biotechnology (NASDAQ:SANA) - MarketBeat
Sana Biotechnology downgraded to Market Perform from Outperform at JMP Securities - MSN
Sana Biotechnology, Inc. Reports Q3 2024 Financial Results - TipRanks
Sana: Q3 Earnings Snapshot - The Washington Post
Sana Biotechnology Inc. (SANA) Quarterly 10-Q Report - Quartzy
Earnings Flash (SANA) SANA BIOTECHNOLOGY Reports Q3 Loss $-0.27 Per Share - Marketscreener.com
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates - The Manila Times
HC Wainwright Issues Positive Estimate for SANA Earnings - Defense World
HC Wainwright Issues Optimistic Forecast for SANA Earnings - MarketBeat
Sana Biotechnology refocuses on autoimmune and diabetes therapies By Investing.com - Investing.com Australia
Sana lowered to market perform by JMP over data uncertainty - MSN
Sana Biotechnology (NASDAQ:SANA) Hits New 52-Week Low on Analyst Downgrade - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Price Target Lowered to $8.00 at HC Wainwright - MarketBeat
Sana Biotechnology stock hits 52-week low at $3.05 - Investing.com
Sana to lay off staff, deepen autoimmune focus in latest retrenchment - BioPharma Dive
500: Something went wrong - Investing.com UK
Sana Biotechnology stock hits 52-week low at $3.05 By Investing.com - Investing.com Canada
JMP Securities Downgrades Sana Biotechnology (NASDAQ:SANA) to Market Perform - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Sana Biotechnology Inc Shares - GuruFocus.com
Sana Biotechnology refocuses on autoimmune and diabetes therapies - Investing.com
Sana Biotechnology Announces Increased Focus on Type 1 - GlobeNewswire
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.6%Here's Why - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Shares Up 7.7%Still a Buy? - MarketBeat
Sana Biotechnology (NASDAQ:SANA) Stock Price Down 6.4%What's Next? - MarketBeat
Critical Comparison: Sana Biotechnology (NASDAQ:SANA) & SAB Biotherapeutics (NASDAQ:SABS) - Defense World
Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Why Sana Biotechnology, Inc. (SANA) is the Penny Stock with the Biggest Upside Potential According to Analysts - Insider Monkey
Biotech stock tumbles after unexplained 1,446% gain - MSN
Sana Biotechnology Inc (SANA) looking to reclaim success with recent performance - SETE News
Sana Biotechnology Inc [SANA] Stock sold by Insider Mulligan Richard for $0.61 million - Knox Daily
Market Insights: Sana Biotechnology Inc (SANA)’s Notable Gain of 4.18, Closing at 3.99 - The Dwinnex
Sana Biotechnology Inc (SANA)’s stock price in review: A technical analysis - US Post News
Sana Biotechnology, Inc. (SANA): Jeff Bezos Is Buying This Stock Now - Insider Monkey
Sana Biotechnology Inc Stock (SANA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sana Biotechnology Inc Stock (SANA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mulligan Richard | Director |
Sep 24 '24 |
Sale |
4.08 |
150,000 |
612,570 |
2,848,121 |
| Mulligan Richard | Director |
Sep 25 '24 |
Sale |
3.89 |
150,000 |
583,170 |
2,698,121 |
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):